Sera collected from 90 multiple sclerosis patients and 148 age-matched normal subjects were examined for the presence of antibodies against human coronaviruses (HCV) 229E and OC43 by enzyme immunoassay (EIA). The results demonstrated no significant difference between the MS patients and the normal subjects in their antibody titer to HCV 229E and HCV OC43. Further analysis of these 238 sera indicated that a stronger EIA reaction was generally observed against HCV OC43 (mean EIA value at an optical density of 492 nm = 0.896) than against HCV 229E (mean EIA value at an optical density of 492 nm = 0.346).
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Multiple sclerosis (MS) is a demyelinating disease of unknown etiology which affects the central nervous system. Over 250,000 individuals in the United States alone suffer from MS (15) . The epidemiological, clinical, and pathological features of MS are consistent with certain known viral infections (8) . Many different viruses have been suggested as etiological agents of MS, including poxviruses, herpesviruses, rhabdoviruses, orthomyxoviruses, paramyxoviruses, and picornaviruses (1, 8, 14) . Recently, the possibility of coronaviruses as etiological agents has been considered because of their role in demyelinating disease in rodents and some reports of association with MS in humans.
The JHM strain of mouse hepatitis virus, a murine coronavirus, is known to cause a demyelinating-remyelinating disease in mice and rats (2, 7, 12 Alexandria, Va.). A control antigen of M-7 lysate diluted to the same concentration was added to the remaining wells. The plates were incubated at 4°C overnight and then treated with carbonate-bicarbonate buffer (pH 9.6) containing 0.5% BSA for 1 h at 37°C. After the plates were washed, absorbed test serum (1:1,000) was added to duplicate wells (300 p1/well) and incubated at 37°C for 1 h. After being washed, 300 ,ul of conjugate diluted 1:8,000 was added to each well and incubated for 1 h at 37°C. Conjugate controls were included on each plate. A 300-pu amount of diluted substrate (o-phenylenediamine dihydrochloride; Sigma Chemical Co., St. Louis, Mo.) was added to each well and incubated at 37°C for 30 min. The reaction was stopped by the addition of 50 ,ul of 2.5 M H2SO4. The optical density at 492 nm (OD492) was read. The EIA values for each serum assayed were determined by the formula EIA value (OD492) = mean (X) OD492 with viral antigen -X OD492 with M-7 cell lysate antigen. Day-to-day variations in the EIA (± 1 standard deviation) were corrected by adjusting the EIA values (OD492) by the value produced by a positive control serum included in each assay.
Fourteen sera from normal subjects were tested by EIA and plaque neutralization for the detection of antibodies to HCV 229E and HCV OC43. The correlation coefficient for comparison with HCV OC43 was 0.80 (Fig. 1A) , and for HCV 229E it was 0.85 (Fig. 1B) . The cut-off value for antibody activity against OC43 was an OD492 of 0.298. This value was based on the comparison of EIA and neutralization data. Similarly, anti-229E antibody was indicated by OD492 values greater than 0.242.
Serum samples taken from 90 MS patients and 148 age-matched normal subjects were then assayed for antibodies to HCV 229E and HCV OC43 by EIA. The results obtained when these two populations were tested by EIA for anti-OC43 activity are shown in Fig. 2 . The data demonstrate that the MS and normal populations reacted similarly to HCV OC43. A total of 84 (93%) MS patients had antibodies to HCV OC43 in their sera (Table 1) . A similar analysis of 148 normal subjects indicated the presence of anti-OC43 activity in the sera of 143 (96%) normal subjects.
The results given in Fig. 3 and summarized in Table 1 were obtained when these same sera were tested by EIA for activity to HCV 229E. The results obtained also indicate no significant difference in the antibody response to HCV 229E between MS patients and the normal control population. Table 1 shows that 45 (50%) MS patients had antibodies to HCV 229E in their sera. Antibody activity to HCV 229E was detected in 85 (57%) normal subjects. Chi-square analysis demonstrated no difference between the two populations with respect to OC43 (X2 = 1.37, a = 0.01) or 229 E (X2 = 1.25, a = 0.01).
A comparison of Fig. 2 and 3 suggested a difference in response to HCV 229E and HCV OC43. The results with HCV 229E were skewed toward lower OD492 values (Fig. 3) . The maximum EIA value (OD492) produced with HCV 229E was 1.600 with sera from normal individuals or MS patients. The mean EIA value (OD492) with HCV 229E was 0.346. EIA values (OD492) observed with HCV OC43 virus ranged from 0 to 3.4 with a mean EIA value (OD492) of 0.8%. The antibody response elicited against HCV OC43 displayed a bimodal distribution (Fig. 2) . Chi-square analysis of the data shown in The results reported here do not support the hypothesis of a role for HCV OC43 or HCV 229E in MS. Although EIA procedures theoretically should detect antibodies to a multiplicity of viral antigens (not just surface glycoproteins), it is still possible that a difference in response may exist in MS with respect to some other antigen of coronaviruses which was not detected by the EIA procedure used.
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